Biochemical Pharmacology volume 79, issue 4, P587-595 2010 DOI: 10.1016/j.bcp.2009.09.025 View full text
|
|
Share
Robert J. Paproski, James D. Young, Carol E. Cass

Abstract: The abundance of human equilibrative nucleoside transporter 1 (hENT1) has recently been shown to be a predictive marker of benefit from gemcitabine therapy in patients with pancreatic cancer. Since hENT1 is also important for the uptake of positron emission tomography (PET) tracer 3'-deoxy-3'-fluorothymidine (FLT) in various cultured human cell lines, this study was undertaken to determine if FLT uptake predicts gemcitabine uptake and/or toxicity in a panel of human pancreatic cancer cell lines (Capan-2, AsPC-…

expand abstract